F-star Therapeutics, Inc.
FSTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.23 | -0.05 | 0.13 |
| FCF Yield | -33.41% | -26.18% | -34.39% | -26.11% |
| EV / EBITDA | -0.62 | -2.33 | -5.64 | -3.14 |
| Quality | ||||
| ROIC | -27.15% | -47.45% | -90.44% | -44.37% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.63 | 0.96 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.25% | – | – | – |
| Free Cash Flow Growth | -64.69% | 23.75% | 18.29% | -51.15% |
| Safety | ||||
| Net Debt / EBITDA | 2.22 | 0.72 | -0.80 | 0.52 |
| Interest Coverage | -36.39 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 39.85 | 129.90 | 146.59 | 0.00 |